Intellix joint venture Icemedix (name changed to Expeda) with professors Björn Ludvikson and Björn Gudbjörnsson at Landspitalet, Reykjavik University Hospital has developed an App for screening individuals for elevated risk for osteoporosis. The medical expert knowledge was captured with the Intellix Designer and a web service was developed by Intellix and hosted in the cloud for powering Expeda’s clinical decision support tool accessed from computers/laptops and smartphone’s via Apps. Intellix have developed both a professional- and a non-professional version for Expeda and the App being introduced today is for the non-professional market.
Viewing entries tagged
The New Business Venture Fund or Nysköpunarsjodur (NSA, www.nsa.is) has agreed to buy shares in Intellix Icelandic joint venture IceMedix ehf. The investment of ISK 55 million will be done in three tranches and thereafter NSA’s share holding in IceMedix will be 27%.
Intellix and the Icelandic corporation IceMedix started their partnership in May 2008. The Osteoporosis Auto-clinical decision making platform is the first product to come out of this partnership. According to IceMedix CEO, Dr. Björn Rúnar Lúðvíksson, it is believed that interactive artificial intelligence complex support systems will become important guiding tools for health care providers towards improved and cost-effective decision-making. “Without Intellix significant contribution and its outstanding artificial intelligence software this achievement would have been near impossible” Dr. Lúðvíksson stated.
The SIMEHealth Project – A Internet based Health Profile and Early Warning Service, which Intellix was chosen to participate in, start Clinical tests in September.
People will, through a tiny hand held device be able to test themselves and connected online to a server, receive continous information about their health and early warning for diseases. In a blood sample of 50 microliter is it possible to verify a large number of specific health issues and diseases.